Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

By F. Bard, C. Cannon, R. Barbour, R. Burke, D. Games, H. Grajeda, T. Guido, K. Hu, Jiping Huang, K. Johnson-wood and 13 more. Nature Medicine, 2000

2,092 citations recorded by the source corpus.

Subfields: Molecular Biology, Neurology, Physiology

View Paper: https://www.semanticscholar.org/paper/b7adaf86ddf636a22be8737968913ee1a703deec

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Neurology

In Physiology

Citations in the corpus

Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation (2005, background): “However, it has been recognized recently that removal of ␤A by activated microglia may be beneficial (Bard et al., 2000; Wyss-Coray et al., 2001; Jantzen et al., 2002 ).”
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease (2014, background): “The carrier study was conducted at 170 sites in the United States from December 2007 through April 2012, and the noncarrier study was conducted at 218 sites in the United States (195 sites), Canada (17), Germany (4), and Austria (2) from December 2007 through June 2012.”
Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model (2007, background): “2002b) and this effect seems to be at least partially mediated by microglial activation (Bard et al. 2000; Wilcock et al. 2003).”
Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice (2001, background): “Therefore, the surface area of the section that is adjudged as positive for A model at 15 months of age (Bard et al., 2000).”
The role of microglia in amyloid clearance from the AD brain (2010, background): “Introduction of anti-Ab antibodies directly into the brain or peripherally resulted in a robust phagocytic response of microglia and consequently the dissolution of Ab deposition in the brain (Bard et al. 2000; Wilcock et al. 2003).”
The amyloid hypothesis of Alzheimer's disease at 25 years (2016, background): “Solanezumab: a probable signal in mild AD Since active and passive immunotherapy to lower amyloid was first conceptualized (Schenk et al, 1999; Bard et al, 2000), antibody trials have taken the lead among putative disease-modifying therapeutics for AD.”
Glycogen Synthase Kinase-3 (GSK3): Inflammation, Diseases, and Therapeutics (2007, background): “In fact, therapeutic intervention by administration of Ab antibodies appears to increase the clearance of Ab by activated microglia [115, 116].”